Innovating For Patients

Trevena is a biopharmaceutical company focused on developing and commercializing novel medicines for patients with central nervous system (CNS) disorders.

About Us

Targeted and Innovative CNS Therapies

Trevena’s novel pipeline includes four product candidates that are being developed for areas of critical need in CNS disorders. All of the company’s pipeline assets are new chemical entities with unique mechanisms of action that target well-known receptors.

Program Molecular Target Therapeutic Target Current Phase PC PH1 PH2 PH3 NDA
Oliceridine Mu receptor Moderate-to-severe acute pain NDA Intravenous PC complete PH1 complete PH2 complete PH3 complete NDA in progress
TRV250 Delta receptor Acute migraine PH1 Oral/Subcutaneous PC complete PH1 in progress PH2 not started PH3 not started NDA not started
TRV734 Mu receptor Opioid use disorder PH1 Oral PC complete PH1 in progress PH2 not started PH3 not started NDA not started
TRV045 S1P receptor CNS disorders PC Oral PC in progress PH1 not started PH2 not started PH3 not started NDA not started
All pipeline assets are Investigational Products not approved by FDA for sale or distribution in the US.

IV oliceridine

Management of moderate-to-severe acute pain in hospital settings.

About IV oliceridine

TRV250

Acute treatment of migraine.

About TRV250

TRV734

Maintenance treatment of opioid use disorder.

About TRV734

TRV045

Treatment of various CNS disorders.

About TRV045